GSK3B and kidney disorder: SAA has also been reported to attenuate injury of kidney disease, which can be attributed to anti-inflammatory and anti-xidative activities by inhibiting the NF-κB and p38 MAPK signaling pathways and activating the Akt/GSK-3β/Nrf2 signaling pathway [37, 48].